Literature DB >> 14967820

Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity.

Tariq Tanoli1, Pin Yue, Dmitriy Yablonskiy, Gustav Schonfeld.   

Abstract

Fatty liver is frequent in the apolipoprotein B (apoB)-defective genetic form of familial hypobetalipoproteinemia (FHBL), but interindividual variability in liver fat is large. To explain this, we assessed the roles of metabolic factors in 32 affected family members with apoB-defective FHBL and 33 related and unrelated normolipidemic controls matched for age, sex, and indices of adiposity. Two hour, 75 g oral glucose tests, with measurements of plasma glucose and insulin levels, body mass index, and waist-hip ratios were obtained. Abdominal subcutaneous, intraperitoneal (IPAT), and retroperitoneal adipose tissue masses were quantified by MR imaging, and hepatic fat was quantified by MR spectroscopy. Mean +/- SD liver fat percentage values of FHBL and controls were 14.8 +/- 12.0 and 5.2 +/- 5.9, respectively (P = 0.001). Means for these measures of obesity and insulin action were similar in the two groups. Important determinants of liver fat percentage were FHBL-affected status, IPAT, and area under the curve (AUC) insulin in both groups, but the strongest predictors were IPAT in FHBL (partial R(2) = 0.55, P < 0.0002) and AUC insulin in controls (partial R(2) = 0.59, P = 0.0001). Regression of liver fat percentage on IPAT fat was significantly greater for FHBL than for controls (P < 0.001). In summary, because apoB-defective FHBL imparts heightened susceptibility to liver triglyceride accumulation, increasing IPAT and insulin resistance exert greater liver fat-increasing effects in FHBL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967820     DOI: 10.1194/jlr.M300508-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  44 in total

1.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

2.  Positron emission tomography detects greater blood flow and less blood flow heterogeneity in the exercising skeletal muscles of old compared with young men during fatiguing contractions.

Authors:  Thorsten Rudroff; Jessica A Weissman; Marco Bucci; Marko Seppänen; Kimmo Kaskinoro; Ilkka Heinonen; Kari K Kalliokoski
Journal:  J Physiol       Date:  2013-11-18       Impact factor: 5.182

Review 3.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

4.  Does inhibition of apolipoprotein B synthesis produce foie gras?

Authors:  Kenneth R Feingold
Journal:  J Lipid Res       Date:  2009-12-30       Impact factor: 5.922

Review 5.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

Review 6.  Molecular mechanisms of fatty liver in obesity.

Authors:  Lixia Gan; Wei Xiang; Bin Xie; Liqing Yu
Journal:  Front Med       Date:  2015-08-19       Impact factor: 4.592

Review 7.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

8.  Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease.

Authors:  I Jane Cox; Amar Sharif; Jeremy F L Cobbold; Howard C Thomas; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

9.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

10.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.